Inactive Instrument

Company Propanc Biopharma Inc Other OTC

Equities

US74346N1072

Biotechnology & Medical Research

Business Summary

Propanc Biopharma, Inc. is an Australia-based clinical biopharmaceutical company. The Company is focused on the development of novel cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. The Company has developed a rational, composite formulation of anti-cancer compounds, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its lead product candidate, PRP, is a variation upon its formulation and involves pro-enzymes, the inactive precursors of enzymes. PRP is a long-term therapy based on a pancreatic proenzyme formulation to prevent tumor recurrence and metastasis. PRP is a patented, formulation consisting of two proenzymes mixed in a synergetic ratio. PRP is in the preclinical phase of development. Its drug pipeline also includes POP1.

Managers

Managers TitleAgeSince
Chief Executive Officer 50 14/10/07
Founder 77 14/10/07
Chief Tech/Sci/R&D Officer - -

Members of the board

Members of the board TitleAgeSince
Chief Executive Officer 50 14/10/07
Founder 77 14/10/07
Director/Board Member 74 22/12/20

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 0 1 0 0 99.78 %
Stock B 1 331,935,348 331,216,641 ( 99.78 %) 0

Shareholders

NameEquities%Valuation
Sylva International LLC
0.4189 %
703,744 0.4189 % 704 $
8,732 0.005198 % 9 $
Julian Kenyon
0.002039 %
3,425 0.002039 % 3 $
Josef Zelinger
0.001670 %
2,806 0.001670 % 3 $
NameEquities%Valuation
1 100.00 % 0 $

Company contact information

Propanc Biopharma, Inc.

6 Butler Street Suite 302

3124, Camberwell

+61 3 9882 0780

http://www.propanc.com
address Propanc Biopharma Inc
  1. Stock Market
  2. Equities
  3. PPCB Stock
  4. Stock
  5. Company Propanc Biopharma Inc